TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided updates across the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback